Use of probiotics in the treatment of crohn's disease

Crohn's Disease: Classification, Diagnosis and Treatment Options

Volumn , Issue , 2013, Pages 287-305

  del Carmen, Silvina ^a   LeBlanc, Jean Guy ^a   de Moreno de LeBlanc, Alejandra ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

Author keywords

Crohn's Disease; Immune regulation; Inflammatory bowel diseases; Lactic acid bacteria; Probiotics

Indexed keywords

EID: 84892254465     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (88)

1. Head, K. A., and Jurenka, J. S. (2003). Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. Altern. Med. Rev., 8, 247-83.
2. Nouaille, S., Ribeiro, L. A., Miyoshi, A., Pontes, D., Le Loir, Y., Oliveira, S. C., Langella, P., and Azevedo, V. (2003). Heterologous protein production and delivery systems for Lactococcus lactis. Genet. Mol. Res., 2, 102-11.
3. LeBlanc, J. G., de Moreno de LeBlanc, A., Perdigón, G., Miyoshi, A., Rochat, T., Bermudez-Humaran, L., Langella, P., Sesma, F., and Azevedo, V. (2008). Anti-inflammatory properties of Lactic Acid Bacteria: Current knowledge, applications and prospects. Anti-Infective Agents in Medicinal Chemistry 7 148-54.
4. FAO/WHO (2001). Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria.
5. Aureli, P., Capurso, L., Castellazzi, A. M., Clerici, M., Giovannini, M., Morelli, L., Poli, A., Pregliasco, F., Salvini, F., and Zuccotti, G. V. (2011). Probiotics and health: an evidence-based review. Pharmacol. Res., 63, 366-76.
6. Galdeano, C. M., de Moreno de LeBlanc, A., Vinderola, G., Bonet, M. E., and Perdigon, G. (2007). Proposed model: mechanisms of immunomodulation induced by probiotic bacteria. Clin. Vaccine Immunol., 14, 485-92.
7. Ouwehand, A. C., Salminen, S., and Isolauri, E. (2002). Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek, 82, 279-89.
8. Isolauri, E., Salminen, S., and Ouwehand, A. C. (2004). Microbial-gut interactions in health and disease. Probiotics. Best Pract. Res. Clin. Gastroenterol., 18, 299-313.
9. del Carmen, S., de Moreno de LeBlanc, A., Miyoshi, A., Santos Rochat, C., Azevedo, V., and LeBlanc, J. G. (2011). Application of probiotics in the prevention and treatment of ulcerative colitis and other inflammatory bowel diseases. Ulcers, 1, 1-13.
10. Tamboli, C. P., Neut, C., Desreumaux, P., and Colombel, J. F. (2004). Dysbiosis in inflammatory bowel disease. Gut, 53, 1-4.
11. Neut, C., Bulois, P., Desreumaux, P., Membre, J. M., Lederman, E., Gambiez, L., Cortot, A., Quandalle, P., van Kruiningen, H., and Colombel, J. F. (2002). Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am. J. Gastroenterol, 97, 939-46.
12. Takaishi, H., Matsuki, T., Nakazawa, A., Takada, T., Kado, S., Asahara, T., Kamada, N., Sakuraba, A., Yajima, T., Higuchi, H., Inoue, N., Ogata, H., Iwao, Y., Nomoto, K., Tanaka, R., and Hibi, T. (2008). Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int. J. Med. Microbiol., 298, 463-72.
13. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L. G., Gratadoux, J. J., Blugeon, S., Bridonneau, C., Furet, J. P., Corthier, G., Grangette, C., Vasquez, N., Pochart, P., Trugnan, G., Thomas, G., Blottiere, H. M., Dore, J., Marteau, P., Seksik, P., and Langella, P. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U S A, 105, 16731-6.
14. Madsen, K. L., Doyle, J. S., Jewell, L. D., Tavernini, M. M., and Fedorak, R. N. (1999). Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology, 116, 1107-14.
15. O'Mahony, L., Feeney, M., O'Halloran, S., Murphy, L., iely, B., Fitzgibbon, J., Lee, G., O'Sullivan, G., Shanahan, F., and Collins, J.K. (2001). Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment. Pharmacol. Ther., 15, 1219-25.
16. Schultz, M., and Lindstrom, A. L. (2008). Rationale for probiotic treatment strategies in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol., 2, 337-55.
17. Fukata, M., and Abreu, M. T. (2007). TLR4 signalling in the intestine in health and disease. Biochem. Soc. Trans, 35, 1473-8.
18. Chaves, S., Perdigon, G., and de Moreno de LeBlanc, A. (2011). Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J. Food Prot., 74, 801-11.
19. de Moreno de LeBlanc, A., Chaves, S., and Perdigon, G. (2009). Effect of yoghhurt on the cytokine profile using a murine model of intestinal inflammation. Eur. J. Inflam. 7 97-109
20. Lee, J., Rachmilewitz, D., and Raz, E. (2006). Homeostatic effects of TLR9 signaling in experimental colitis. Ann. N Y Acad. Sci., 1072, 351-5.
21. Venturi, A., Gionchetti, P., Rizzello, F., Johansson, R., Zucconi, E., Brigidi, P., Matteuzzi, D., and Campieri, M. (1999). Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol. Ther., 13, 1103-8.
22. Klaenhammer, T. (1988). Bacteriocins of lactic acid bacteria. Biochimie, 70, 337-49.
23. Flynn, S., van Sinderen, D., and Thornton, G. (2002). Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118. Microbiology, 148, 973-84.
24. Rea, M., Clayton, E., and O'Connor, P. (2007). Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J. Med. Microbiol, 56, 940-6.
25. Schultz, M., Munro, K., Tannock, G. W., Melchner, I., Göttl, C., Schwietz, H., Schölmerich, J., and Rath, H. C. (2004). Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats. Clin. Diagn. Lab. Immunol., 11, 581-7.
26. Campieri, M., Rizzello, F., Venturi, A., Poggioli, G., Ugolini, F., Helwig, U., Amasini, C., Romboli, E., and Gionchetti, P. (2000). Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomised controlled study v. mesalazine. Gastroenterology, 118, A4179.
27. Weiner, H. L., Gonnella, P. A., Slavin, A., and Maron, R. (1997). Oral tolerance: cytokine milieu in the gut and modulation of tolerance by cytokines. Res Immunol, 148, 528-33.
28. O'Sullivan, D. J. (2001). Screening of intestinal microflora for effective probiotic bacteria. J. Agric. Food Chem., 49, 1751-60.
29. de Moreno de LeBlanc, A., del Carmen, S., Zurita-Turk, M., Santos Rochat, C., van de Guchte, M., Azevedo, V., Miyoshi, A., and LeBlanc, J. G. (2011). Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterology, 1, 1-10
30. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K., and Muller, W. (1993). Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 75, 263-74.
31. Tilg, H., van Montfrans, C., van den Ende, A., Kaser, A., van Deventer, S. J., Schreiber, S., Gregor, M., Ludwiczek, O., Rutgeerts, P., Gasche, C., Koningsberger, J. C., Abreu, L., Kuhn, I., Cohard, M., LeBeaut, A., Grint, P., and Weiss, G. (2002). Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut, 50, 191-5.
32. Schmitz, H., Barmeyer, C., Fromm, M. L., Runkel, N., Foss, H. D., Bentzel, C. J., Riecken, E. O., and Schulzke, J. D. (1999). Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology, 116, 301-9.
33. Hilsden, R. J., Meddings, J. B., and Sutherland, L. R. (1996). Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology, 110, 1395-403.
34. Ng, S. C., Hart, A. L., Kamm, M. A., Stagg, A. J., and Knight, S. C. (2009). Mechanisms of action of probiotics: recent advances. Inflammatory bowel diseases, 15, 300-10.
35. Meddings, J. (2008). The significance of the gut barrier in disease. Gut, 57, 438.
36. Madsen, K., Cornish, A., Soper, P., McKaigney, C., Jijon, H., Yachimec, C., Doyle, J., Jewell, L., and De Simone, C. (2001). Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology, 121, 580-91.
37. Mao, Y., Nobaek, S., Kasravi, B., Adawi, D., Stenram, U., Molin, G., and Jeppsson, B. (1996). The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology, 111, 334-44.
38. Garcia-Lafuente, A., Antolin, M., Guarner, F., Crespo, E., and Malagelada, J. R. (2001). Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut, 48, 503.
39. Mack, D. R., Michail, S., Wei, S., McDougall, L., and Hollingsworth, M. A. (1999). Probiotics inhibit enteropathogenic E. coliadherence in vitro by inducing intestinal mucin gene expression. American Journal of Physiology-Gastrointestinal and Liver Physiology, 276, G941.
40. Otte, J., and Podolsky, D. (2004). Functional modulation of enterocytes by Gram-positive and Gram-negative microorganisms. Am. J. Physiol. Gastrointest Liver. Physiol., 286, G613-G26.
41. Szatrowski, T. P., and Nathan, C. F. (1991). Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res., 51, 794-8.
42. Kruidenier, L., van Meeteren, M. E., Kuiper, I., Jaarsma, D., Lamers, C. B., Zijlstra, F. J., and Verspaget, H. W. (2003). Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radic. Biol. Med., 34, 753-65.
43. Sanders, J. W., Leenhouts, K. J., Haandrikman, A. J., Venema, G., and Kok, J. (1995). Stress response in Lactococcus lactis: cloning, expression analysis, and mutation of the lactococcal superoxide dismutase gene. J. Bacteriol., 177, 5254-60.
44. Kullisaar, T., Zilmer, M., and Mikelsaar, M. (2002). Two antioxidative lactobacilli strains as promising probiotics. Int. J. Food Microbiol., 72, 215-24.
45. Segui, J., Gironella, M., Sans, M., Granell, S., Gil, F., Gimeno, M., Coronel, P., Pique, J. M., and Panes, J. (2004). Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. J. Leukoc. Biol., 76, 537-44.
46. Rochat, T., Miyoshi, A., Gratadoux, J. J., Duwat, P., Sourice, S., Azevedo, V., and Langella, P. (2005). High-level resistance to oxidative stress in Lactococcus lactis conferred by Bacillus subtilis catalase KatE. Microbiology, 151, 3011-8.
47. Abriouel, H., Herrmann, A., Starke, J., Yousif, N. M., Wijaya, A., Tauscher, B., Holzapfel, W., and Franz, C. M. (2004). Cloning and heterologous expression of hematin-dependent catalase produced by Lactobacillus plantarum CNRZ 1228. Appl. Environ. Microbiol., 70, 603-6.
48. Knauf, H. J., Vogel, R. F., and Hammes, W. P. (1992). Cloning, sequence, and phenotypic expression of katA, which encodes the catalase of Lactobacillus sake LTH677. Appl. Environ. Microbiol., 58, 832-9.
49. Noonpakdee, W., Sitthimonchai, S., Panyim, S., and Lertsiri, S. (2004). Expression of the catalase gene katA in starter culture Lactobacillus plantarum TISTR850 tolerates oxidative stress and reduces lipid oxidation in fermented meat product. Int. J. Food Microbiol., 95, 127-35.
50. Zakostelska, Z., Kverka, M., Klimesova, K., Rossmann, P., Mrazek, J., Kopecny, J., Hornova, M., Srutkova, D., Hudcovic, T., Ridl, J., and Tlaskalova-Hogenova, H. (2011). Lysate of Probiotic Lactobacillus casei DN-114 001 Ameliorates Colitis by Strengthening the Gut Barrier Function and Changing the Gut Microenvironment. PLoS One, 6, e27961.
51. Matsuguchi, T., Takagi, A., Matsuzaki, T., Nagaoka, M., Ishikawa, K., Yokokura, T., and Yoshikai, Y. (2003). Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin. Diagn. Lab. Immunol., 10, 259-66.
52. Claes, I. J., Lebeer, S., Shen, C., Verhoeven, T. L., Dilissen, E., De Hertogh, G., Bullens, D. M., Ceuppens, J. L., Van Assche, G., Vermeire, S., Rutgeerts, P., Vanderleyden, J., and De Keersmaecker, S. C. (2010). Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis. Clin. Exp. Immunol., 162, 306-14.
53. Jurjus, A. R., Khoury, N. N., and Reimund, J.-M. (2004). Animal models of inflammatory bowel disease. Journal of Pharmacological and Toxicological Methods, 50, 81-92.
54. Hormannsperger, G., Clavel, T., Hoffmann, M., Reiff, C., Kelly, D., Loh, G., Blaut, M., Holzlwimmer, G., and Haller, D. (2010). Posttranslational inhibition of proinflammatory chemokine secretion in intestinal epithelial cells: implications for specific IBD indications. J. Clin. Gastroenterol., 44 SUPPL 1, S10-5.
55. Matsumoto, S., Hara, T., Hori, T., Mitsuyama, K., Nagaoka, M., Tomiyasu, N., Suzuki, A., and Sata, M. (2005). Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin. Exp. Immunol., 140, 417-26.
56. Herias, M. V., Koninkx, J. F., Vos, J. G., Huis in't Veld, J. H., and van Dijk, J. E. (2005). Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int. J. Food Microbiol., 103, 143-55.
57. Grabig, A., Paclik, D., Guzy, C., Dankof, A., Baumgart, D. C., Erckenbrecht, J., Raupach, B., Sonnenborn, U., Eckert, J., Schumann, R. R., Wiedenmann, B., Dignass, A. U., and Sturm, A. (2006). Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect. Immun., 74, 4075-82.
58. Lee, H. S., Han, S. Y., Bae, E. A., Huh, C. S., Ahn, Y. T., Lee, J. H., and Kim, D. H. (2008). Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice. Int. Immunopharmacol, 8, 574-80.
59. Nishitani, Y., Tanoue, T., Yamada, K., Ishida, T., Yoshida, M., Azuma, T., and Mizuno, M. (2009). Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Int. Immunopharmacol., 9, 1444-51.
60. Peran, L., Camuesco, D., Comalada, M., Nieto, A., Concha, A., Diaz-Ropero, M. P., Olivares, M., Xaus, J., Zarzuelo, A., and Galvez, J. (2005). Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J. Gastroenterol, 11, 5185-92.
61. Peran, L., Sierra, S., Comalada, M., Lara-Villoslada, F., Bailon, E., Nieto, A., Concha, A., Olivares, M., Zarzuelo, A., Xaus, J., and Galvez, J. (2007). A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br. J. Nutr., 97, 96-103.
62. Philippe, D., Heupel, E., Blum-Sperisen, S., and Riedel, C. U. (2011). Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. Int. J. Food Microbiol., 149, 45-9.
63. Duary, R. K., Bhausaheb, M. A., Batish, V. K., and Grover, S. (2011). Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model. Mol. Biol. Rep.
64. Lee, B., Lee, J. H., Lee, H. S., Bae, E. A., Huh, C. S., Ahn, Y. T., and Kim, D. H. (2009). Glycosaminoglycan degradation-inhibitory lactic acid bacteria ameliorate 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. J. Microbiol. Biotechnol., 19, 616-21.
65. Foligne, B., Zoumpopoulou, G., Dewulf, J., Ben Younes, A., Chareyre, F., Sirard, J. C., Pot, B., and Grangette, C. (2007). A key role of dendritic cells in probiotic functionality. PLoS One, 2, e313.
66. Hedin, C. R., Mullard, M., Sharratt, E., Jansen, C., Sanderson, J. D., Shirlaw, P., Howe, L. C., Djemal, S., Stagg, A. J., Lindsay, J. O., and Whelan, K. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm. Bowel. Dis., 16, 2099-108.
67. Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., and Campieri, M. (2003). Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology, 124, 1202-9.
68. Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I. C., Nicholls, R. J., Gionchetti, P., Campieri, M., and Kamm, M. A. (2004). Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut, 53, 108-14.
69. Rachmilewitz, D., Katakura, K., Karmeli, F., Hayashi, T., Reinus, C., Rudensky, B., Akira, S., Takeda, K., Lee, J., Takabayashi, K., and Raz, E. (2004). Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology, 126, 520-8.
70. Ulisse, S., Gionchetti, P., D'Alo, S., Russo, F. P., Pesce, I., Ricci, G., Rizzello, F., Helwig, U., Cifone, M. G., Campieri, M., and De Simone, C. (2001). Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am. J. Gastroenterol, 96, 2691-9.
71. Feghali, C. A., and Wright, T. M. (1997). Cytokines in acute and chronic inflammation. Front Biosci., 2, d12-26.
72. Miele, E., Pascarella, F., Giannetti, E., Quaglietta, L., Baldassano, R. N., and Staiano, A. (2009). Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol, 104, 437-43.
73. Gupta, P., Andrew, H., Kirschner, B. S., and Guandalini, S. (2000). Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol Nutr., 31, 453-7.
74. Carol, M., Borruel, N., Antolin, M., Llopis, M., Casellas, F., Guarner, F., and Malagelada, J. R. (2006). Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J. Leukoc. Biol., 79, 917-22.
75. Guslandi, M., Mezzi, G., Sorghi, M., and Testoni, P. A. (2000). Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci., 45, 1462-4.
76. Malin, M., Suomalainen, H., Saxelin, M., and Isolauri, E. (1996). Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann. Nutr. Metab., 40, 137-45.
77. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., and Quigley, E. M. (2005). Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology, 128, 541-51.
78. Cui, H. H., Chen, C. L., Wang, J. D., Yang, Y. J., Cun, Y., Wu, J. B., Liu, Y. H., Dan, H. L., Jian, Y. T., and Chen, X. Q. (2004). Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J. Gastroenterol, 10, 1521-5.
79. Kajander, K., and Korpela, R. (2006). Clinical studies on alleviating the symptoms of irritable bowel syndrome. Asia Pac. J. Clin. Nutr., 15, 576-80.
80. Bittner, A. C., Croffut, R. M., Stranahan, M. C., and Yokelson, T. N. (2007). Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial. Clin. Ther., 29, 1153-60.
81. Bittner, A. C., Croffut, R. M., and Stranahan, M. C. (2005). Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin. Ther., 27, 755-61.
82. Choi, C. H., Jo, S. Y., Park, H. J., Chang, S. K., Byeon, J. S., and Myung, S. J. (2011). A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J. Clin. Gastroenterol., 45, 679-83.
83. Pronio, A., Montesani, C., Butteroni, C., Vecchione, S., Mumolo, G., Vestri, A., Vitolo, D., and Boirivant, M. (2008). Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel. Dis., 14, 662-8.
84. Furrie, E., Macfarlane, S., Kennedy, A., Cummings, J. H., Walsh, S. V., O'Neil D, A., and Macfarlane, G. T. (2005). Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut, 54, 242-9.
85. Kruis, W., Fric, P., Pokrotnieks, J., Lukas, M., Fixa, B., Kascak, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., Wolff, C., and Schulze, J. (2004). Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 53, 1617-23.
86. Tursi, A., Brandimarte, G., Giorgetti, G. M., Forti, G., Modeo, M. E., and Gigliobianco, A. (2004). Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med. Sci. Monit., 10, PI126-31.
87. Karimi, O., Pena, A. S., and van Bodegraven, A. A. (2005). Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. Drugs Today (Barc), 41, 453-9.
88. Mallon, P., McKay, D., Kirk, S., and Gardiner, K. (2007). Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., CD005573.